drugset / Trial / NCT02160678

Generic Tazarotene Cream, 0.1% in the Treatment of Acne Vulgaris

NCT02160678

Phase 3 Completed 1741 enrolled G & W Laboratories Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

To compare the safety and efficacy profiles of Tazarotene Cream, 0.1 % to the reference listed drug Tazorac® (tazarotene) Cream, 0.1 % in order to demonstrate bioequivalence, and to demonstrate superiority of the 2 active creams over that of the cream vehicle (placebo) in the treatment of acne vulgaris.

Timeline

Start
2014-05
Primary completion
2015-07
Completion
2015-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Tazarotene Small molecule 0.1 % Topical

Indications